MX2007003546A - Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa. - Google Patents
Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.Info
- Publication number
- MX2007003546A MX2007003546A MX2007003546A MX2007003546A MX2007003546A MX 2007003546 A MX2007003546 A MX 2007003546A MX 2007003546 A MX2007003546 A MX 2007003546A MX 2007003546 A MX2007003546 A MX 2007003546A MX 2007003546 A MX2007003546 A MX 2007003546A
- Authority
- MX
- Mexico
- Prior art keywords
- indozolone
- derivatives
- hsd1 inhibitors
- formula
- hsd1
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen los compuestos de la formula (I) (Ver Formula) asi como las sales y esteres farmaceuticamente aceptables de los mismos, en la que R1 a R7 tienen los significados definidos en la descripcion y en las reivindicaciones, los cuales se pueden utilizar en forma de composiciones farmaceuticas. Los compuestos de la formula (I) son inhibidores 11b-HSD1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04104753 | 2004-09-29 | ||
| PCT/EP2005/010175 WO2006034804A1 (en) | 2004-09-29 | 2005-09-21 | Indozolone derivatives as 11b-hsd1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007003546A true MX2007003546A (es) | 2007-05-18 |
Family
ID=35447579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007003546A MX2007003546A (es) | 2004-09-29 | 2005-09-21 | Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7528158B2 (es) |
| EP (1) | EP1797042B1 (es) |
| JP (1) | JP4682207B2 (es) |
| KR (1) | KR100856164B1 (es) |
| CN (1) | CN101027286B (es) |
| AR (1) | AR050952A1 (es) |
| AT (1) | ATE420076T1 (es) |
| AU (1) | AU2005289107B2 (es) |
| BR (1) | BRPI0515931A (es) |
| CA (1) | CA2581865C (es) |
| DE (1) | DE602005012292D1 (es) |
| DK (1) | DK1797042T3 (es) |
| ES (1) | ES2317305T3 (es) |
| HR (1) | HRP20090151T3 (es) |
| IL (1) | IL182212A (es) |
| MX (1) | MX2007003546A (es) |
| MY (1) | MY140841A (es) |
| NO (1) | NO20071617L (es) |
| NZ (1) | NZ553849A (es) |
| PL (1) | PL1797042T3 (es) |
| PT (1) | PT1797042E (es) |
| RU (1) | RU2392272C2 (es) |
| SG (1) | SG148178A1 (es) |
| SI (1) | SI1797042T1 (es) |
| TW (1) | TWI309646B (es) |
| WO (1) | WO2006034804A1 (es) |
| ZA (1) | ZA200702394B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| US8318941B2 (en) | 2006-07-06 | 2012-11-27 | Bristol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| CL2008001839A1 (es) | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20090076783A1 (en) * | 2007-09-13 | 2009-03-19 | Tyco Healthcare Retail Services Ag | Digitally optimized fastener assembly and method of making the same |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| CA2716136A1 (en) * | 2008-03-06 | 2009-09-11 | William P. Dankulich | Hexahydrocyclopentyl[f]indazole sulfonamides and derivatives thereof as selective glucocorticoid receptor modulators |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| BR112012003973A2 (pt) | 2009-08-26 | 2015-09-08 | Sanofi Sa | hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
| KR101796781B1 (ko) | 2016-05-20 | 2017-11-13 | 한국화학연구원 | 신규한 인다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 질환의 예방 또는 치료용 약학적 조성물 |
| JP7446316B2 (ja) | 2019-01-11 | 2024-03-08 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換ピロリジンアミドｉｉｉ |
| US12398097B2 (en) | 2019-07-29 | 2025-08-26 | Vanderbilt University | WDR5-MYC inhibitors |
| US20240132431A1 (en) * | 2021-01-06 | 2024-04-25 | Chugai Seiyaku Kabushiki Kaisha | Method for alkylating acidic functional group |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL84944A (en) * | 1987-01-19 | 1992-02-16 | Ici Plc | Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation |
| GB9805520D0 (en) | 1998-03-17 | 1998-05-13 | Zeneca Ltd | Chemical compounds |
| SE0001899D0 (sv) * | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| FR2836914B1 (fr) * | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| EP2399903A1 (en) | 2002-05-24 | 2011-12-28 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
| JP2007514731A (ja) * | 2003-12-19 | 2007-06-07 | ファイザー インコーポレイテッド | 糖尿病及び肥満症の治療のための１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型（１１−β−ｈｓｄ−１）の阻害剤としてのベンゼンスルホニルアミノ−ピリジン−２−イル誘導体及び関連化合物 |
-
2005
- 2005-09-21 BR BRPI0515931-8A patent/BRPI0515931A/pt not_active IP Right Cessation
- 2005-09-21 AT AT05791184T patent/ATE420076T1/de active
- 2005-09-21 PL PL05791184T patent/PL1797042T3/pl unknown
- 2005-09-21 KR KR1020077007018A patent/KR100856164B1/ko not_active Expired - Fee Related
- 2005-09-21 ES ES05791184T patent/ES2317305T3/es not_active Expired - Lifetime
- 2005-09-21 MX MX2007003546A patent/MX2007003546A/es active IP Right Grant
- 2005-09-21 SG SG200808470-9A patent/SG148178A1/en unknown
- 2005-09-21 DE DE602005012292T patent/DE602005012292D1/de not_active Expired - Lifetime
- 2005-09-21 PT PT05791184T patent/PT1797042E/pt unknown
- 2005-09-21 NZ NZ553849A patent/NZ553849A/en not_active IP Right Cessation
- 2005-09-21 DK DK05791184T patent/DK1797042T3/da active
- 2005-09-21 AU AU2005289107A patent/AU2005289107B2/en not_active Ceased
- 2005-09-21 EP EP05791184A patent/EP1797042B1/en not_active Expired - Lifetime
- 2005-09-21 CA CA2581865A patent/CA2581865C/en not_active Expired - Fee Related
- 2005-09-21 JP JP2007533911A patent/JP4682207B2/ja not_active Expired - Fee Related
- 2005-09-21 CN CN2005800322682A patent/CN101027286B/zh not_active Expired - Fee Related
- 2005-09-21 RU RU2007116033/04A patent/RU2392272C2/ru not_active IP Right Cessation
- 2005-09-21 HR HR20090151T patent/HRP20090151T3/xx unknown
- 2005-09-21 WO PCT/EP2005/010175 patent/WO2006034804A1/en not_active Ceased
- 2005-09-21 SI SI200530605T patent/SI1797042T1/sl unknown
- 2005-09-26 US US11/235,375 patent/US7528158B2/en not_active Expired - Fee Related
- 2005-09-26 AR ARP050104014A patent/AR050952A1/es unknown
- 2005-09-26 TW TW094133289A patent/TWI309646B/zh not_active IP Right Cessation
- 2005-09-27 MY MYPI20054555A patent/MY140841A/en unknown
-
2007
- 2007-03-22 ZA ZA200702394A patent/ZA200702394B/xx unknown
- 2007-03-26 IL IL182212A patent/IL182212A/en not_active IP Right Cessation
- 2007-03-27 NO NO20071617A patent/NO20071617L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007003546A (es) | Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa. | |
| TW200608972A (en) | Aryl-pyridine derivatives | |
| IN2012DN03337A (es) | ||
| TW200738241A (en) | Pyridazine derivatives | |
| MX2009003939A (es) | Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes. | |
| MX2009004441A (es) | Derivados de indazol utiles como inhibidores de las isoformas de higado. | |
| MX2010005824A (es) | Derivados de aminotiazol. | |
| TW200526658A (en) | Heterocyclic inhibitors of MEK and methods of use thereof | |
| MX2010006799A (es) | Benzofuropirimidinonas como inhibidores de la proteina cinasa. | |
| MX2010001535A (es) | Derivados de acido azabifenilaminobenzoico como inhibidores de la dihidroorotato deshidrogenasa. | |
| MX2010002584A (es) | Derivados de piperidina como agonistas de receptores muscarinicos. | |
| TW200833324A (en) | Sulfonamide derivatives | |
| MX2008016426A (es) | Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1). | |
| TW200716628A (en) | Novel compounds | |
| MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
| TW200745032A (en) | Novel heterobicyclic derivatives | |
| TW200722421A (en) | Azole derivatives as inhibitors of lipases and phospholipases | |
| MX2010006108A (es) | Inhibidores de estearoil-coa-desaturasa. | |
| GB0314967D0 (en) | Piperazine derivatives | |
| UA99787C2 (en) | Lactams as beta secretase inhibitors | |
| MX2007003913A (es) | Alquil-piridinas como inhibidores de 11 beta para diabetes. | |
| IN2012DN01232A (es) | ||
| MX2009003169A (es) | Derivados de sulfonamida. | |
| TW200730513A (en) | Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases | |
| TW200740764A (en) | Pyrazolone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| HH | Correction or change in general |